222 related articles for article (PubMed ID: 15633227)
1. Giant malignant gastrointestinal stromal tumors: recurrence and effects of treatment with STI-571.
Chen TW; Liu HD; Shyu RY; Yu JC; Shih ML; Chang TM; Hsieh CB
World J Gastroenterol; 2005 Jan; 11(2):260-3. PubMed ID: 15633227
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
3. Surgical treatment of gastrointestinal stromal tumors in the imatinib (STI-571) era.
Wu PC; Langerman A; Ryan CW; Hart J; Swiger S; Posner MC
Surgery; 2003 Oct; 134(4):656-65; discussion 665-6. PubMed ID: 14605627
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review.
Miettinen M; El-Rifai W; H L Sobin L; Lasota J
Hum Pathol; 2002 May; 33(5):478-83. PubMed ID: 12094372
[TBL] [Abstract][Full Text] [Related]
5. Gastrointestinal stromal tumors (GIST): a single center experience.
Kostka R; Gürlich R; Koldová L
Acta Chir Belg; 2012 Jan; 112(1):33-9. PubMed ID: 22442907
[TBL] [Abstract][Full Text] [Related]
6. Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate?
Scaife CL; Hunt KK; Patel SR; Benjamin RS; Burgess MA; Chen LL; Trent J; Raymond AK; Cormier JN; Pisters PW; Pollock RE; Feig BW
Am J Surg; 2003 Dec; 186(6):665-9. PubMed ID: 14672776
[TBL] [Abstract][Full Text] [Related]
7. Gastrointestinal stromal tumors: overview of pathologic features, molecular biology, and therapy with imatinib mesylate.
Koh JS; Trent J; Chen L; El-Naggar A; Hunt K; Pollock R; Zhang W
Histol Histopathol; 2004 Apr; 19(2):565-74. PubMed ID: 15024716
[TBL] [Abstract][Full Text] [Related]
8. Clinical management of gastrointestinal stromal tumors: before and after STI-571.
Dematteo RP; Heinrich MC; El-Rifai WM; Demetri G
Hum Pathol; 2002 May; 33(5):466-77. PubMed ID: 12094371
[TBL] [Abstract][Full Text] [Related]
9. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.
Dagher R; Cohen M; Williams G; Rothmann M; Gobburu J; Robbie G; Rahman A; Chen G; Staten A; Griebel D; Pazdur R
Clin Cancer Res; 2002 Oct; 8(10):3034-8. PubMed ID: 12374669
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
Saito S; Nakata K; Kajiura S; Ando T; Hosokawa A; Sugiyama T
Digestion; 2013; 87(1):47-52. PubMed ID: 23343969
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for primary gastrointestinal stromal tumours: are they the same in the multidisciplinary treatment era?
Cananzi FC; Lorenzi B; Belgaumkar A; Benson C; Judson I; Mudan S
Langenbecks Arch Surg; 2014 Mar; 399(3):323-32. PubMed ID: 24413830
[TBL] [Abstract][Full Text] [Related]
12. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
Du CY; Zhou Y; Song C; Wang YP; Jie ZG; He YL; Liang XB; Cao H; Yan ZS; Shi YQ
Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330
[TBL] [Abstract][Full Text] [Related]
13. Current management of gastrointestinal stromal tumors--a comprehensive review.
Lai EC; Lau SH; Lau WY
Int J Surg; 2012; 10(7):334-40. PubMed ID: 22633986
[TBL] [Abstract][Full Text] [Related]
14. Feasibility and Timing of Cytoreduction Surgery in Advanced (Metastatic or Recurrent) Gastrointestinal Stromal Tumors During the Era of Imatinib.
Chang SC; Liao CH; Wang SY; Tsai CY; Chiang KC; Cheng CT; Yeh TS; Chen YY; Ma MC; Liu CT; Yeh CN
Medicine (Baltimore); 2015 Jun; 94(24):e1014. PubMed ID: 26091448
[TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal stromal tumors: diagnosis and treatment.
Acín-Gándara D; Pereira-Pérez F; Castaño-Pascual A; Durán-Poveda M; Antequera-Pérez A; Miliani-Molina C
Cir Cir; 2012; 80(1):44-51. PubMed ID: 22472152
[TBL] [Abstract][Full Text] [Related]
16. Cystic changes in hepatic and peritoneal metastases from gastrointestinal stromal tumors treated with Gleevec.
Bechtold RE; Chen MY; Stanton CA; Savage PD; Levine EA
Abdom Imaging; 2003; 28(6):808-14. PubMed ID: 14753595
[TBL] [Abstract][Full Text] [Related]
17. [Clinical analysis of 156 patients with gastrointestinal stromal tumors receiving imatinib therapy].
Zhang L; Cai M; Deng J; Wang X; Wang B; Liu N; Pan Y; Zhang R; Cui Q; Liang H
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Apr; 17(4):331-4. PubMed ID: 24760639
[TBL] [Abstract][Full Text] [Related]
18. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.
Andtbacka RH; Ng CS; Scaife CL; Cormier JN; Hunt KK; Pisters PW; Pollock RE; Benjamin RS; Burgess MA; Chen LL; Trent J; Patel SR; Raymond K; Feig BW
Ann Surg Oncol; 2007 Jan; 14(1):14-24. PubMed ID: 17072676
[TBL] [Abstract][Full Text] [Related]
19. Prognostic factors in surgically managed gastrointestinal stromal tumours.
Wu XJ; Zhang RX; Chen G; Fang YJ; Ding PR; Li LR; Lu ZH; Kong LH; Pan ZZ; Wan DS
J Int Med Res; 2012; 40(5):1904-11. PubMed ID: 23206474
[TBL] [Abstract][Full Text] [Related]
20. Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: implications of imatinib mesylate.
Yeh CN; Chen TW; Wu TJ; Hsueh S; Jan YY
World J Gastroenterol; 2006 Jun; 12(23):3760-5. PubMed ID: 16773696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]